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Western blotAbstract Background: Integrin Linked Kinase (ILK), Snail and Multidrug Resistance Protein 1
(MRP1) have been implicated in several cancers; however, their roles in non-small cell lung cancer
(NSCLC) remain to be elucidated.
Aim: Investigation of their expression in NSCLC tissue. Relationships among these proteins and
their association with clinicopathological parameters were studied.
Materials and methods: ILK, Snail and MRP1 expression were immunohistochemically assessed in
97 tumor tissues. Furthermore, western blot analysis for ILK, Snail and MRP1 in 6 cases of
NSCLC was also performed.
Results: ILK overexpression, positive Snail and MRP1 expression were found in 46.4%, 36.1%
and 49.5% of tumors respectively. ILK expression was signiﬁcantly correlated with tumor grade
(p= 0.013), lymph node (LN) metastases (p= 0.001) and stage (p= 0.001). Positive Snail and
MRP1 expression were signiﬁcantly associated with LN metastasis (p= 0.004 and 0.022, respec-
tively) and advanced stage disease (p= 0.018 and 0.024, respectively). MRP1 expression was
signiﬁcantly higher among adenocarcinoma cases compared to other types (p= 0.001). ILK
over-expression was signiﬁcantly associated with up-regulation of Snail and MRP1 (p< 0.001
both). Signiﬁcant association was also, found between Snail and MRP1 expression
(p= 0.005). Moreover, the co-expression of two markers or more was signiﬁcantly associated
with less differentiation (p= 0.011), advanced tumor status (p= 0.030), LN metastasis
(p< 0.001) and advanced stage (p< 0.001) disease. Western blot analysis validated immunohis-
tochemical ﬁndings.45348.
130 D.M. Abd El-Rehim et al.Conclusion: ILK may have an important role in the progression of NSCLC, possibly through
up-regulation of Snail and MRP1. ILK, Snail and MRP1 are important molecular markers for
predicting carcinogenesis and progression of NSCLC.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Lung cancer, particularly non-small cell lung cancer (NSCLC),
is one of the most common malignancies and the leading
causes of cancer-related mortality worldwide [1].
The prognosis of NSCLC patients is generally poor espe-
cially in advanced stage disease, where less than 10% of
patients survive beyond 5 years [2]. Tumor metastasis and ther-
apeutic resistance are the major causes of the disease recur-
rence and treatment failure [3]. Acquisition of invasive and
migratory abilities and the development of drug resistance in
cancer cells result primarily from adopting an epithelial-
mesenchymal transition (EMT) phenotype [4–6].
EMT is a complex molecular and cellular process of pheno-
typic switch of polarized epithelial cells into motile mesenchy-
mal cells. Alterations in cellular adhesion, morphology,
architecture and migration potential are the major events char-
acterizing this process [6]. EMT was initially described during
embryonic development and tissue repair and more recently in
cancer progression, where it induces an invasion–metastasis
cascade and confers multidrug resistance (MDR) phenotype
on cancer cells [4–7]. MDR is a major obstacle on effective
treatment of cancer. It participates in cancer metastasis and
recurrence, resulting in a more aggressive tumor than that seen
at the start of treatment [5]. Therefore, understanding of the
molecular basis of these processes for identiﬁcation of poten-
tial cancer-targeted therapeutic strategies is fundamental.
As a novel EMT regulator, ILK has attracted widespread
attention. Its role in governing the metastatic ability in various
cancers, predominantly by acquiring the mesenchymal
phenotype has been documented [8–10].
ILK, an intracellular serine/threonine kinase protein, is a
downstream substrate of the phosphoinositide 3-kinase
(PI-3K) pathway. It interacts with cytoplasmic domains of
b-integrin subunits and regulates integrin dependent functions.
ILK plays an important role in transducing many of the
signals that are initiated by cell–matrix interactions and that
regulate many biological processes [11].
ILK overexpression was reported in many types of human
cancers including NCSLC [8,9,12]. Its overexpression pro-
motes oncogenic transformation of cancer cells via regulation
of several downstream targets that promote cancer cell prolif-
eration, survival, metastasis and angiogenesis. Recently, the
development of ILK inhibitors has provided novel mecha-
nisms for blocking ILK signaling aiming at controlling tumor
metastasis and therapy resistance [8,11].
Snail (SNAI1) transcription factor which belongs to the
Snail superfamily of zinc ﬁnger proteins has a central role in
inducing the EMT process in physiologic and pathologic situ-
ations and triggering invasive activities of cancer cells [6]. This
is partly mediated by controlling genes that regulate tightjunction stability, epithelial cell polarity and morphology. It
interacts with Smad3 and Smad4 to form a transcriptional
repressor complex which targets the gene promoters of CAR
(a tight-junction protein), occludin, claudin-3 as well as E-
cadherin during EMT in cancer cells [13]. Snail has also been
found to upregulate the expression of matrix metalloproteases
(MMPs) such as MMP9 [14].
Development of MDR is a major deterrent in the effective
treatment of cancers by chemotherapy. Multidrug resistance
protein 1 (MRP1/ABCC1) is a key member of the ATP-
binding cassette (ABC) transporter superfamily proteins.
These proteins are involved in the trans-membrane efﬂux of
a wide spectrum of anticancer drugs from the intracellular
compartment to the extracellular one, thus decreasing their
intracellular concentration thereby leading to MDR.
Overexpression of MRP1 has been detected in a variety of
tumors (15–17) and is associated with poor patient outcome
in NSCLC (15, 17).
A growing body of evidence has demonstrated a close
relationship connecting EMT, increased invasive and meta-
static abilities as well as drug resistance in several cancers
including NSCLC [4,5,9,18–20]. However, a comprehensive
study of the molecular elements underlying EMT and their
association with NSCLC progression and drug resistance
has not been conducted, yet. The present study hypothesized
that the expression of ILK, Snail and MRP1 might play an
important role in NSCLC progression and assumed that
ILK may be involved in acquiring the EMT and MDR phe-
notypes in NSCLC. In this series of NSCLC, the expression
of ILK, Snail and MRP1 and their association with clinico-
pathological data were estimated using immunohistochem-
istry. The presence of possible associations among these
proteins and the effect of their combined expression on
NSCLC progression were also evaluated. In addition, western
blot analysis for ILK, Snail and MRP1 in 6 cases of NSCLC
was performed.
Materials and methods
Tissue specimens
The current work comprised 97 specimens of NSCLC. Cases
were diagnosed between 2007 and 2014 in the Departments
of Pathology, Minia University Hospital and Minia
Oncology Centre, Egypt. The corresponding clinicopathologi-
cal information was obtained from patients’ medical records.
Tumor histotype and tumor grade of differentiation were
revised according to World Health Organization (WHO) crite-
ria, 2004. Tumor staging was done according to Tumor, Node
and Metastasis Classiﬁcation System, AJCC Cancer Staging
Manual, sixth edition [21].
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Four lm thick tissue sections were deparafﬁnized in xylene
and rehydrated in graded ethanol. Endogenous peroxidase
activity was blocked by incubation with 0.3% Hydrogen
peroxide/Methanol for 30 min. Antigen retrieval was achieved
by microwave treatment of slides in sodium citrate buffer
(0.01 M, pH 6.0) for 10 min. Sections were subsequently incu-
bated with primary monoclonal antibodies against ILK (clone
65.1, Santa Cruz Biotechnology, Inc., diluted at 1/100), MRP1
(clone QCRL-1, Santa Cruz Biotechnology, Inc., diluted at
1/100) and polyclonal antibody against SNAIL (abcam,
diluted at 1/50). Visualization of the reaction was performed
with an avidin biotin complex immunoperoxidase system using
3,30 diamino-benzidine (DAB) as a chromogen for 10 min.
Finally, sections were counterstained with hematoxylin, dehy-
drated, and mounted.
Sections of human renal tissue that were obtained from
normal margins after nephrectomy of renal cell carcinoma
cases were used as positive controls for ILK and MRP1
expression. Sections of ovarian cancer with known positive
Snail protein expression were used as positive controls for
Snail expression. The negative controls were prepared by
replacing the primary antibodies with phosphate-buffered sal-
ine (PBS).
Scoring system
Because of the heterogeneous pattern of ILK expression,
staining was scored semiquantitatively by multiplication of
the percentage of positive tumor cells and staining intensity
as reported in a previous study [9]. Initially, the intensity of
staining was graded as follows: 0 = negative; 1 += weak
positive; 2 +=moderate positive; and 3 += strong positive.
Thereafter, the percentage of positive cells was scored as: 0
(0%); 1+(1–10%); 2+(11–50%); and 3+(51–100%). The
product of intensity and percentage scores ranged between 0
and 9. The immunoreactivity of tumor tissues was ﬁnally
determined as low-level ILK expression (with a score 62)
and high-level ILK expression (with a score P3), according
to the median level of expression. For evaluation of Snail
[22] and MRP1 [23] expressions, sections that exhibited stain-
ing in P10% and >20%, respectively of the tumor cells were
classiﬁed as positive.
Western blotting
Extraction of proteins from lung cancer cells was performed
using NE-PER extraction reagents (Pierce, Rockford, IL) with
a protease inhibitor cocktail (Sigma–Aldrich). Upon determi-
nation of individual protein concentrations of the samples
using the Bradford assay [24], 6 fresh samples were prepared
for loading. Electrophoresis and electro-blotting were carried
out in a Bio-Rad Mini-Protein II Cell apparatus (Bio-Rad
Laboratories, Hemel Hempstead, UK) using a discontinuous
buffer system. Aliquots of equal amounts of lysate lung sam-
ples were separated on a 12% gradient Tris-glycine gel
(Invitrogen) under denaturing conditions using Tris-glycine
SDS running buffer (Invitrogen). Proteins were electroblotted
to a nitrocellulose membrane (Invitrogen). Brieﬂy, after incu-
bation in blocking solution, 5% Blotto non-fat dry milk(Santa Cruz) for 60 min at room temperature, the membranes
were incubated (overnight at 4 C) with primary monoclonal
antibodies against ILK (clone 65.1, Santa Cruz
Biotechnology, INC., diluted at 1/100) and MRP1 (clone
QCRL-1, Santa Cruz Biotechnology, INC., diluted at 1/100)
and polyclonal antibody against Snail (abcam, diluted at
1/100). B-actin was used as a loading control to ensure equal
loading and even transfer from the gel to the membrane across
the whole gel. The membranes were washed and incubated
with secondary antibody conjugated to alkaline phosphatase
at room temperature for 60 min. Alkaline phosphatase label-
ing was detected using chromogenic substrate containing 5-b
romo-4-chloro-3-indolyl-1-phosphate and nitroblue tetra-
zolium substrate. Cross-reacting bands were visualized by
enhanced chemiluminescence.Statistical analysis
The relationships among ILK, Snail and MRP1 expression as
well as their relationships to clinicopathological parameters
were analyzed using the Chi-square and Fisher’s exact tests.
Median was used as a cutoff point for ILK expression.
Statistical signiﬁcance was accepted at the p 6 0.05 level. All
analyses were performed using SPSS Version 11.0.
Results
Patients’ and tumor characteristics
Patients’ and tumor characteristics are summarized in Table 1.
The patients mean age ±SD was 60.92 ± 8.53 years (range,
41–75 years) at the time of diagnosis. The majority of
NSCLC patients were male patients (n= 82).
The immunoreactivity of ILK was mainly in the cytoplasm
of tumor cells with a heterogeneous expression pattern.
Among cases, 45/97 (46.4%) were classiﬁed as ILK overex-
pressing tumors (expression score P3) while 52/97 (53.6%)
of the samples had an expression score 62 (Fig. 1a and b).
Nuclear Snail (Fig. 1c) and cytoplasmic/membranous MRP1
(Fig. 1d) expressions were detected in 35/97 (36.1%) and
48/97 (49.5%) of tumors respectively.
The associations between ILK, Snail and MRP1 with the
clinicopathological parameters are summarized in Table 2. A
signiﬁcant positive association was found between ILK overex-
pression and histological grade, lymph node metastasis and
TNM stage of the tumor (p= 0.013, 0.001 and 0.001, respec-
tively). Positive Snail and MRP1 expression were signiﬁcantly
associated with lymph node metastasis (p= 0.004 and 0.022,
respectively) and tumor advanced stage (p= 0.018 and
0.024, respectively). Positive MRP1 was signiﬁcantly associ-
ated with histological tumor type (p= 0.001), being higher
in lung adenocarcinomas compared to other histological types
and in female patients compared to males (p= 0.012).
Associations among markers and the clinicopathological effect
of their combined expression
The relationships among ILK, Snail and MRP1 proteins were
outlined in Table 3. Overexpression of ILK signiﬁcantly
correlated with anomalous positivity of Snail and MRP1
Table 1 Clinicopathological features of 97 cases of NSCLC.
Clinicopathological features N (%)
Gender
Male 82 (84.5%)
Female 15 (15.5%)
Age
660 years 45 (46.4%)
>60 years 52 (53.6%)
Histological tumor type
Adenocarcinoma 47 (48.5%)
Squamous cell carcinoma 39 (40.2%)
Large cell carcinoma 11 (11.5%)
Grade
1 10 (10.3%)
2 38 (39.2%)
3 49 (50.5%)
Tumor status
T1 13 (13.4%)
T2 57 (58.8%)
T3 23 (23.7%)
T4 4 (4.1%)
Nodal status
N0 41 (42.3%)
N1 31 (32.0%)
N2 25 (25.8%)
Stage
I 38 (39.2%)
II 25 (25.8%)
III 28 (28.8%)
IV 6 (6.2%)
132 D.M. Abd El-Rehim et al.(p< 0.001). Likewise, Snail expression was signiﬁcantly asso-
ciated with MRP1 expression (p= 0.005). To investigate the
clinicopathological implications of the cumulative effects of
the three proteins on the progression of NSCLC, tumors were
stratiﬁed according to the number of positive markers into 2
groups. The ﬁrst group included none positive and one-
marker positive tumors while the second group comprised
two-marker positive and all-marker positive tumors. Tumor
categorized as all-marker positive and two-marker positive
were more frequently associated with aggressive features
including increased grade (p= 0.011), advanced tumor status
(T3 and T4) (p= 0.030), LN spread (p< 0.001), advanced
stage (p< 0.001) disease and large cell carcinoma type
(p= 0.05), compared to the group of none positive and one-
marker positive tumors (Fig. 1e–g and Table 4).
Western blotting
Protein extracts of 6 NSCLC samples were used to perform
western blotting to validate the expression of ILK, Snail and
MRP1 proteins assessed by immunohistochemistry. Results
of western blotting and immunohistochemistry were in concert
(Table 5 and Fig. 2).
Discussion
This study investigated ILK, Snail and MRP1 expression in
NSCLC. ILK overexpression was detected in 46.4% ofNSCLC. Its overexpression was signiﬁcantly correlated with
advanced TNM stage, lymph node metastasis and tumor
grade. These results are consistent with previous studies in
NSCLC [9,12] as well as in other malignancies [8,10,25,26],
where ILK expression was strongly correlated with poor prog-
nostic features and linked to tumor invasion, metastasis, and
angiogenesis. These ﬁndings along with ours support a possible
role of ILK as an oncogene. On the contrary, other studies
showed reduced ILK in breast and renal carcinomas compared
to normal tissues [27,28]. Furthermore, Chen and his co-
authors reported that overexpression of ILK in breast cancer
cells suppresses the growth and invasion in vitro and tumor
formation and metastases in vivo [27], suggesting a tumor sup-
pressor role for ILK. However, the current available evidence
is more in favor of the oncogenic function of ILK in tumors
[8–10,25,26].
Snail is a signiﬁcant EMT inducer. Its upregulation has
been reported to play a role in lung cancer progression, mainly
by enhancing invasiveness and metastatic behavior [9,29–31],
inducing tumor cell proliferation, angiogenesis [29] and stem
cell properties [31]. Consistent with these reports, the current
study identiﬁed apparent Snail expression in 36.1% of cases
and showed signiﬁcant associations between Snail upregula-
tion and nodal spread and advanced stage disease, conﬁrming
the correlation between EMT and aggressive behavior in
NSCLC.
In the current work, immunohistochemistry localized Snail
protein expression to the nucleus of tumor cells. Several studies
demonstrated nuclear subcellular localization of Snail
[29,30,32] while another study reported cytoplasmic Snail
expression in tumor cells [22]. Posttranslational mechanisms
have been reported to control Snail activity by regulating its
stability and subcellular localization. Glycogen synthase
kinase-3 b (GSK-3b) phosphorylation of Snail induces its cyto-
plasmic export, sustained cytoplasmic accumulation and
ubiquitin-mediated proteasomal degradation. Thus, it prevents
it from functioning in the nucleus as a transcription factor [33].
On the other hand, interaction with the inﬂammatory microen-
vironment leads to NFjB–mediated nuclear stabilization of
Snail [34]. In this series, Snail sustains a nuclear localization,
indicating that it is transcriptionally active in NSCLC. This
also, highlighted the importance of Snail protein subcellular
localization in NSCLC biology and its potential to be a target
for cancer therapy.
The mechanism of MDR in NSCLC is likely to be multifac-
torial [35]. One of the most important mechanisms underlying
MDR is overexpression of ABC transporters [16]. Herein, the
positive expression rate of MRP1 was 49.5% among NSCLC
cases. Previous studies reported MRP1 expression in
NSCLC, with positive expression rates between 21% and
81% [15,17,23,36,37], indicating that this protein is commonly
expressed in NSCLC and suggesting its role in the chemo-
resistant biology and incurable nature of this tumor.
In agreement with a previous study [23], the current study
showed a signiﬁcant association between MRP1-positive
expression rates and both TNM stage and lymph node metas-
tasis. However, another study did not ﬁnd such relationships
[15]. The present work together with other studies [15,17],
reported signiﬁcantly higher MRP1 expression rates in adeno-
carcinoma compared to other histological types of NSCLC. In
addition, two previous studies reported stronger drug resis-
tance in adenocarcinoma than that in squamous cell carcinoma
Figure 1 (a–g) Immunohistochemical expression of ILK, Snail and MRP1 in NSCLC tissues. Tumors show low and high ILK
expression scores (a, b), positive Snail (c) and MRP1 (d) expression. Positive co-expression of ILK (e), Snail (f) and MRP1 (g) in a case of
large cell carcinoma using anti-ILK, Snail and MRP1 antibodies, diaminobenzidine as a chromogen and hematoxylin as a counterstain
(Magniﬁcation 400·).
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were signiﬁcantly higher in the former than in the latter
[37,38]. More recently, another study demonstrated that the
endogenous expression of multidrug resistance related proteins
was different in the four human lung cancer cell lines derived
from different histological types, and this difference may beassociated with the variation in sensitivity to different
chemotherapeutics used in lung cancer [39], suggesting an asso-
ciation between MDR phenotype and the histological tumor
type in NSCLC.
On studying the association between ILK and Snail in
NSCLC cases, our results showed signiﬁcant association
Table 2 Associations of ILK, Snail and MRP1 expression and different clinicopathological features.
Clinicopathological features Total Markers expression
ILK over-expression p-value Positive Snail p-value Positive MRP1 p-value
Gender
Male 82 36 (43.9%) 0.274 31 (37.8%) 0.562 36 (43.9%) 0.012
Female 15 9 (60.0%) 4 (26.7%) 12 (80.0%)
Age
660 years 45 22 (48.9%) 0.687 19 (42.2%) 0.291 23 (51.1%) 0.84
>60 years 52 23 (44.2%) 16 (30.8%) 25 (48.1%)
Histological tumor type
Adenocarcinoma 47 24 (51.1%) 0.429 16 (34.0%) 0.123 32 (68.1%) 0.001
Squamous cell carcinoma 39 15 (38.5%) 12 (30.8%) 11 (28.2%)
Large cell carcinoma 11 6 (54.5%) 7 (63.6%) 5 (45.5%)
Grade
1 10 1 (10.0%) 0.013 1 (10.0%) 0.121 4 (40.0%) 0.215
2 38 23 (60.5%) 17 (44.7%) 23 (60.5%)
3 49 21 (42.9%) 17 (34.7%) 21 (42.9%)
Tumor status
T1 13 5 (38.5%) 0.097 5 (38.5%) 0.354 7 (53.8%) 0.15
T2 57 22 (38.6%) 18 (31.6%) 23 (40.4%)
T3 23 15 (65.2%) 9 (39.1%) 15 (65.2%)
T4 4 3 (75.0%) 3 (75.5%) 3 (75.5%)
Nodal status
N0 41 10 (24.4%) 0.001 7 (17.1%) 0.004 14 (34.1%) 0.022
N1 31 18 (58.1%) 16 (51.6%) 17 (54.8%)
N2 25 17 (68.0%) 12 (48.0%) 17 (68.0%)
Stage
I 38 10 (26.3%) 0.001 7 (18.4%) 0.018 14 (36.8%) 0.024
II 25 10 (40.0%) 10 (40.0%) 10 (40.0%)
III 28 20 (71.4%) 14 (50.0%) 20 (71.4%)
IV 6 5 (83.3%) 4 (66.7%) 4 (66.7%)
Table 3 Associations among ILK, Snail and MPR expression.
Snail MRP
Negative Positive p-value Negative Positive p-value
ILK
Low expression 44 (84.6%) 8 (15.4%) <0.001 39 (75%) 13 (25%) <0.001
Overexpression 18 (40%) 27 (60%) 10 (22.2%) 35 (77.8%)
Snail – – –
Negative 38 (61.3%) 24 (38.7%) 0.005
Positive 11 (31.4%) 24 (68.6%)
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which might indicate a causative link between ILK over-
expression and Snail upregulation. This ﬁnding is consistent
with previous results demonstrating the direct regulation of
EMT markers, including Snail, by ILK in several tumors
including NSCLC [8,9,40]. A strong positive association
between ILK and MRP1 expression was also found. Such a
ﬁnding needs to be conﬁrmed in a larger cohort of NSCLC.
A previous study [20] showed that ILK silencing downregu-
lated the expression of MRP1 in human gastric carcinoma
SGC7901/DDP cells and suggested ILK as a potential thera-
peutic strategy to combat multi-drug resistance.There is accumulating evidence to support a close relation-
ship between EMT phentotype and multidrug resistance in
malignant tumors. Malignant cells undergoing EMT become
more drug resistant [4,18,19]. The EMT-inducing transcription
factors Snail, Slug and Twist promote overexpression of ABC
drug transporters by directly modulating their promoter activ-
ity [5]. On the other hand, drug-resistant cancer cells derived
by long-term exposure to chemotherapeutic drugs have been
shown to acquire mesenchymal morphology, increased inva-
sive and migratory abilities as well as enhanced expression of
EMT-regulating transcription factors [5,41]. In agreement with
these reports, this study found a signiﬁcant positive association
Table 4 Associations of the cumulative ILK, Snail and MRP1 expression and different clinicopathological features.
ILK/Snail/MRP1 cumulative expression
Clinicopathological features Total None/one +ve Two/all +ve p-value
Gender
Male 82 47 (57.3%) 35 (42.7%) 0.215
Female 15 6 (40%) 9 (60.0%)
Age
660 years 45 23 (51.1%) 22 (48.9%) 0.516
>60 years 52 30 (57.7%) 22 (42.3%)
Histological tumor type
Adenocarcinoma 47 22 (46.8%) 25 (53.2%) 0.05
Squamous cell carcinoma 39 27 (69.2%) 12 (30.8%)
Large cell carcinoma 11 4 (36.4%) 7 (63.6%)
Grade
1 10 9 (90.0%) 1 (10.0%) 0.011
2 38 15 (39.5%) 23 (60.5%)
3 49 29 (59.2%) 20 (40.8%)
Tumor status
T1 13 8 (61.5%) 5 (38.5%) 0.03
T2 57 36 (63.2%) 21 (36.8%)
T3 23 9 (39.1%) 14 (60.9%)
T4 4 0 4 (100%)
Nodal status
N0 41 32 (78%) 9 (22%) <0.001
N1 31 13 (41.9%) 18 (58.1%)
N2 25 8 (32%) 17 (68%)
Stage
I 38 29 (76.3%) 9 (23.7%) <0.001
II 25 14 (56%) 11 (44.0%)
III 28 10 (35.7%) 18 (64.3%)
IV 6 0 6 (100%)
Table 5 Details of cases selected for western blotting analysis.
Case Diagnosis Markers expression as detected by
Immunohistochemistry
ILK Snail MRP1
1 SCC Overexpression Positive Positive
2 SCC Overexpression Positive Positive
3 Adenocarcinoma Overexpression Positive Positive
4 Adenocarcinoma Overexpression Positive Positive
5 SCC Negative Negative Negative
6 Adenocarcinoma Negative Negative Negative
SCC, squamous cell carcinoma.
Figure 2 Western blotting analysis for MRP1, ILK and Snail
proteins in six cancer lung tissue samples. B-actin was used to
measure the relative expression of all proteins loaded in the six
lanes. The relative expression of MRP1, ILK and Snail in the cases
from 1 to 4 showed moderate to strong expression as compared to
that of B-actin expression. Lanes 5 and 6 showed no expression for
any of the antibodies used.
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ciation between EMT and MDR phenotypes in NSCLC.
The clinicopathological signiﬁcance of the cumulative
effects of the three proteins on progression of NSCLC was also
evaluated. This study showed that the co-expression of two
markers or more was signiﬁcantly found among cases with
increased tumor grade, advanced tumor status (T3 and T4)
and stage, nodal metastasis and large cell carcinoma suggesting
a cooperative role of these proteins in the progression of
NSCLC. This goes in line with two recent studies that have
demonstrated that ILK positively regulates malignant cellmigration and invasion through enhancing EMT in NSCLC
[9] and colorectal carcinoma [10].
To validate the immunohistochemical ﬁndings of ILK,
Snail and MRP1, their detection in 6 cases of NSCLC tissues
using western blotting was also conducted. Results of western
blotting matched and correlated with those obtained by
immunohistochemistry.
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In conclusion, ILK is overexpressed in NSCLC and
seems to play a role in the up-regulation of Snail and
MRP1, contributing to the acquisition of more aggressive
and invasive properties of NSCLC. Also detected is the signif-
icant positive relationship among ILK, Snail and MRP1
expression; suggesting a potential role for ILK in regulating
EMT and MDR phenotypes in NSCLC. The expression of
drug efﬂux pump, MRP1 is common in NSCLC particularly
among adenocarcinoma cases and signiﬁcantly correlated with
Snail expression, indicating a close association between EMT
and drug resistance phenotypes. Given the role of EMT in
promoting chemoresistance and acquiring aggressive and
invasive properties in NSCLC, speciﬁc targeting of EMT could
potentially serve to overcome drug resistance and decrease
metastasis; however, future additional work is needed in order
to conﬁrm these suggestions.Conﬂict of interest
None.
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